An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer's Disease.

Trial Profile

An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer's Disease.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2016

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 10 Aug 2016 The trial was completed in Belgium.
    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top